The deal is sourced from a joint press release filed as an 8-K exhibit by ANI Pharmaceuticals on June 21, 2024, announcing the signed agreement, with a closing-confirmation 8-K filed later in September 2024 after the deal completed.
Perella Weinberg Partners served as a financial advisor to Alimera, the target, in a non-lead capacity alongside lead advisor Centerview Partners LLC. The release states: "Centerview Partners LLC is acting as lead financial advisor to Alimera, with Perella Weinberg Partners also acting as a financial advisor to Alimera." On the acquirer side, Raymond James & Associates, Inc. is also named as a financial advisor to ANI, though the sentence structure ("is also acting as financial advisor") suggests an additional advisor to ANI's primary deal team not fully captured in the excerpt.
Hughes Hubbard & Reed LLP served as legal advisor to ANI, and DLA Piper served as legal advisor to Alimera.
The transaction valued Alimera at approximately $381 million in upfront consideration, consistent with the $5.50-per-share cash price before the CVR. The deal was expected to close late in the third quarter of 2024, subject to customary closing conditions including regulatory approvals and Alimera shareholder approval; it subsequently closed, per the separately filed closing 8-K dated September 16, 2024.
Not disclosed in the reviewed excerpt: the specific net revenue targets that would trigger CVR payment, the identity and role of ANI's lead financial advisor (if distinct from Raymond James), and the maximum aggregate CVR payout value across all Alimera shares.